Acadian Asset Management LLC Acquires 254,607 Shares of 10x Genomics $TXG

Key Points

• Acadian Asset Management LLC increased its stake in 10x Genomics (NASDAQ:TXG) by 167.7% during the first quarter, holding 406,405 shares worth $3,543,000.
• Many institutional investors, including UBS AM and Millennium Management LLC, have significantly boosted their positions in 10x Genomics, contributing to 84.68% of the stock being owned by such investors.
• The company reported earnings of $0.28 per share for the latest quarter, surpassing estimates and marking a revenue increase of 12.9% year-over-year.

Acadian Asset Management LLC raised its holdings in 10x Genomics (NASDAQ:TXG - Free Report) by 167.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 406,405 shares of the company's stock after acquiring an additional 254,607 shares during the quarter. Acadian Asset Management LLC owned about 0.33% of 10x Genomics worth $3,543,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new position in 10x Genomics in the fourth quarter valued at approximately $32,000. GAMMA Investing LLC boosted its stake in 10x Genomics by 81.8% in the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock valued at $31,000 after acquiring an additional 1,614 shares during the last quarter. Signaturefd LLC boosted its stake in 10x Genomics by 134.3% in the first quarter. Signaturefd LLC now owns 4,203 shares of the company's stock valued at $37,000 after acquiring an additional 2,409 shares during the last quarter. Whittier Trust Co. bought a new position in 10x Genomics in the first quarter valued at approximately $41,000. Finally, PNC Financial Services Group Inc. boosted its stake in 10x Genomics by 153.6% in the first quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company's stock valued at $45,000 after acquiring an additional 3,119 shares during the last quarter. 84.68% of the stock is owned by institutional investors.

10x Genomics Stock Down 1.7%

TXG traded down $0.23 during trading on Friday, hitting $13.04. The company had a trading volume of 3,262,793 shares, compared to its average volume of 2,167,720. The company has a market capitalization of $1.62 billion, a PE ratio of -18.63 and a beta of 2.00. 10x Genomics has a one year low of $6.78 and a one year high of $23.53. The firm's 50-day moving average price is $13.29 and its 200 day moving average price is $10.90.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.63. The business had revenue of $172.91 million for the quarter, compared to analysts' expectations of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The firm's revenue was up 12.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. Sell-side analysts forecast that 10x Genomics will post -1.43 earnings per share for the current year.

Insider Activity at 10x Genomics

In related news, insider Benjamin J. Hindson sold 7,486 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the sale, the insider directly owned 440,888 shares of the company's stock, valued at approximately $6,079,845.52. The trade was a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Serge Saxonov sold 9,348 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the completion of the sale, the chief executive officer directly owned 945,892 shares in the company, valued at $13,043,850.68. This represents a 0.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 39,149 shares of company stock valued at $539,865. 9.39% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have issued reports on TXG shares. UBS Group raised their price objective on shares of 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Morgan Stanley reduced their price target on shares of 10x Genomics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 12th. Zacks Research cut shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 5th. Deutsche Bank Aktiengesellschaft set a $14.00 price target on shares of 10x Genomics and gave the stock a "hold" rating in a research report on Friday, August 8th. Finally, Canaccord Genuity Group set a $16.00 price target on shares of 10x Genomics in a research report on Monday, August 11th. Six investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, 10x Genomics presently has a consensus rating of "Hold" and an average price target of $13.65.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.